A restart from within: Molecular Health is becoming Lucera. After years of shifting corporate fortunes, a substantial part of Heidelberg-based Molecular Health is continuing in a new form. An investor consortium has acquired the company’s pharma technology business and relaunched it as Lucera GmbH. Dr Friedrich von Bohlen remains at the helm, while Dr Stephan Brock, the mind behind the Dataome data engine, also stays on board as CTO.
IMU Biosciences secures US$53m to decode the immune system
Latest NewsLondon-based IMU Biosciences has expanded its Series A financing to more than US$53m (£40m/€46m) in an oversubscribed round, as the company looks to scale its immune-profiling platform and move further into clinical applications.
Abivax delivers Phase 3 ulcerative colitis win, but safety concerns trigger market sell-off
Latest NewsParisian Abivax shared positive topline results for its Phase 3 trial in ulcerative colitis. Its investigational oral, first-in-class miR-124 enhancer, dubbed obefazimod, met all primary and secondary endpoints, yet investors reacted negatively.
A fresh start for Molecular Health: technology core becomes start-up Lucera
Latest NewsA restart from within: Molecular Health is becoming Lucera. After years of shifting corporate fortunes, a substantial part of Heidelberg-based Molecular Health is continuing in a new form. An investor consortium has acquired the company’s pharma technology business and relaunched it as Lucera GmbH. Dr Friedrich von Bohlen remains at the helm, while Dr Stephan Brock, the mind behind the Dataome data engine, also stays on board as CTO.
Greywolf reports early responses with oral ERAP1 inhibitor in solid tumours
Latest NewsOxford-based Greywolf Therapeutics has reported early clinical activity for its first-in-class oral ERAP1 inhibitor GRWD5769 in combination with the anti-PD-1 antibody cemiplimab across six solid tumour types, presenting Phase 1b data from the EMITT-1 trial at the 2026 ASCO Annual Meeting.
ASCO: Immatics posts data on PRAME pipeline ahead of pivotal readout
Latest NewsImmatics has published a series of updates on its PRAME pipeline, using the American Society for Clinical Oncology (ASCO) Annual Meeting to share data on its lead candidate and next-generation program.
Oculis drops plans for diabetic macular edema drug after Phase III miss
Latest NewsSwiss ophthalmology biotech Oculis has suffered a major setback for its most advanced ophthalmology programme after two pivotal Phase III trials of OCS-01 eye drops in diabetic macular edema failed to meet their primary endpoint.
Servier buys Edgewise muscular dystrophy business for up to US$2.65bn
Latest NewsFrench pharmaceutical group Servier has agreed to acquire sevasemten and the muscular dystrophy business built around it from US biotech Edgewise Therapeutics Inc. in a transaction worth up to US$2.65bn, giving the Paris-based company a late-stage entry into Becker and Duchenne muscular dystrophy.
T-CURX buys Pantherna as the race for in vivo CAR-T gathers pace
Latest NewsT-CURX acquires Pantherna: does this mark the start of a new race for the next generation of CAR-T therapies? The Würzburg- and Munich-based CAR-T company T-CURX is acquiring the Berlin-based mRNA and LNP company Pantherna Therapeutics. Financial details of the transaction were not disclosed. Pantherna is to continue operating in Hennigsdorf as a wholly owned subsidiary.
MS expert takes the helm
AppointmentsErik Lundgren assumed his role as the new CEO of Immunic. He succeeds Dr Daniel Vitt, who will continue to oversee the biotech company’s scientific strategy.
Standing Together in Uncertain Times
Sponsored PublicationsChemspec Europe returned to Cologne between 6-7 May 2026, drawing 4,238 attendees from 60 nations and 454 exhibitors from 28 countries, an increase from last year’s event.